DYN · Categories · Coverage
DYN - Analyst coverage initiated
Dyne Therapeutics Inc. (DYN) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for DYN
- Bernstein initiated coverage on Dyne Therapeutics with a new price targetBernstein initiated coverage of Dyne Therapeutics with a rating of Mkt Perform and set a new price target of $13.00
- Evercore ISI initiated coverage on Dyne Therapeutics with a new price targetEvercore ISI initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $46.00
- BMO Capital Markets initiated coverage on Dyne Therapeutics with a new price targetBMO Capital Markets initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $50.00
- Scotiabank initiated coverage on Dyne Therapeutics with a new price targetScotiabank initiated coverage of Dyne Therapeutics with a rating of Sector Outperform and set a new price target of $50.00
- Robert W. Baird initiated coverage on Dyne Therapeutics with a new price targetRobert W. Baird initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $46.00
- RBC Capital Mkts initiated coverage on Dyne Therapeutics with a new price targetRBC Capital Mkts initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $45.00
- Morgan Stanley initiated coverage on Dyne Therapeutics with a new price targetMorgan Stanley initiated coverage of Dyne Therapeutics with a rating of Overweight and set a new price target of $40.00
- H.C. Wainwright initiated coverage on Dyne Therapeutics with a new price targetH.C. Wainwright initiated coverage of Dyne Therapeutics with a rating of Buy and set a new price target of $36.00
- Oppenheimer initiated coverage on Dyne Therapeutics with a new price targetOppenheimer initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $34.00
- Guggenheim initiated coverage on Dyne Therapeutics with a new price targetGuggenheim initiated coverage of Dyne Therapeutics with a rating of Buy and set a new price target of $33.00
- Chardan Capital Markets initiated coverage on Dyne Therapeutics with a new price targetChardan Capital Markets initiated coverage of Dyne Therapeutics with a rating of Buy and set a new price target of $17.00
- Raymond James initiated coverage on Dyne Therapeutics with a new price targetRaymond James initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $15.00
- Jonestrading initiated coverage on Dyne TherapeuticsJonestrading initiated coverage of Dyne Therapeutics with a rating of Buy